How profitable is Chemed Corp (CHE)?

In FY 2025 (10-K), CHE converted $2.5B of revenue into a 32.5% gross margin, 13.4% operating margin, and $325.5M in free cash flow (12.9% FCF margin).

Stock Ratings / Health Care / CHE / financials

HIMS (60) LFST (67) OPCH (74) BTSG (67) ⌘ Pro Terminal →

Chemed Corp (CHE) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$542.18 +1.40% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $544.85

Chemed Corp (CHE) earns a Roarable Rating of A- (Buy) with 83/100 RQD Confidence. High-quality cash engine (32.5% gross margin, 23% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE A- • BUY Cap $6.96B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CHE Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CHE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Chemed Corp (NYSE: CHE) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 83/100 at a spot price of $542.18 (+1.40% 1D, market cap $6.96B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, CHE ranks #11 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CHE compare to HIMS and LFST in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), CHE carries a Roarable A- (83/100 RQD), trailing P/E of N/A, gross margin of 32.5%, and ROIC of 23.4%. By comparison, HIMS (Hims & Hers Health Inc.) holds a C- grade (60/100 RQD, P/E 53.9x, ROIC 8.4%, cap $6.46B) and LFST (LifeStance Health Group Inc.) posts a C+ grade (67/100 RQD, P/E N/A, ROIC 1.2%, cap $5.12B). Among the 5-stock peer group, OPCH leads on earnings multiple (23.0x) while CHE leads on capital efficiency (23.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CHE?

▼

Per CHE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000019584), Chemed Corp generated $2.53B in revenue (+65.3% YoY), $265.2K in net income, and $325.5M in free cash flow against $1.54B in total assets and $251.5M in total debt. Key quantitative strengths: Strong cash generator (32.5% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $544.84 (+0.49%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 12.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 83/100 (A-) historically ranked in the Top 7% of excess returns over the next 90 days (+8.7% avg 90D alpha vs SPY • 72.2% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • A-

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk A-

Each axis scored 0–20

12M PRICE TARGET CONE+11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CHE)Realized 20D OHLCV Swing Band: ±4.9%

Deterministic 5-Pillar Attribution (83/100 Composite)

🔍 WHY CHE SCORES 83/100 (A-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (22% of score)

Altman Z-Score 12.68 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 12.9% FCF Margin ($325.5M FCF) & 32.5% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution16/20 pts (-4 pt drag)

Cannibal Buyback (-2.36% YoY Shares) & executive Form 4 sales trim 4 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$513.18-0.4% Next Q

Q2 (-2Q)

Grade A-$511.37+4.3% Next Q

Q3 (-1Q)

Grade A-$533.36+1.7% Next Q

Current

Grade A-$542.18+8.7% Hist 90D α

Trajectory: B+ (75) → A- (83)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CHE Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 83/100 (A-) score, CHE faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 30.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($514.59) or 200D SMA ($464.05) invalidates the momentum regime and cuts Target Base ($603.18) toward Bear Floor ($444.59).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CHE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CHE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 83%NO 17%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CHE Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$325.5M (12.9% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.32B

FY24

Rev $1.53B

FY25

Rev $2.53B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$2.53B	32.5%	13.4%	$265.2K	$325.5M	23.1%
FY 2024	$1.53B	32.5%	23.9%	$302.0K	$368.0M	24.4%
FY 2023	$1.32B	32.5%	25.9%	$272.5K	$271.1M	11.4%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CHE)

✓Walkthrough of CHE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CHE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +27.30%▲ ASCENDING TRIANGLE

2026-11-03O $541.9H $542.2L $534.7C $542.2VOL 180.5K

RES: $562.7SUP: $499.7SMA50: $514.6SMA200: $464.1

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CHE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CHE Butterfly Map → + Track CHE →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

16.9%/yr Implied 5Y Growth

vs. +65.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CHE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CHE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CHE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CHE)

Health Care Rank #11 of 1015 ⚔️ HIMS vs CHE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CHE vs. HIMS, LFST, OPCH, BTSG)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Chemed Corp (CHE) ranks #11 by composite RQD confidence (83/100, grade A-) and #134 by equity capitalization ($6.96B). Within this direct 5-issuer industry benchmark cohort, OPCH leads on earnings valuation at 23.0x trailing P/E, while CHE leads on capital efficiency and profitability with 23.4% ROIC and 32.5% gross margin. CHE currently leads its immediate peer cohort in composite quantitative strength at 83/100 (A-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CHE ACTIVE Chemed Corp	A-	83/100	—	32.5%	23.4%	+1.40%	$6.96B	Benchmark Subject
HIMS Hims & Hers Health Inc.	C-	60/100	53.9x	73.8%	8.4%	-8.81%	$6.46B	/hims-vs-che →
LFST LifeStance Health Group Inc.	C+	67/100	—	—	1.2%	-1.04%	$5.12B	/lfst-vs-che →
OPCH Option Care Health Inc.	B	74/100	23.0x	19.3%	11.9%	-0.44%	$4.77B	/opch-vs-che →
BTSG BrightSpring Health Services Inc.	C+	67/100	63.0x	11.8%	5.5%	-0.94%	$13.24B	/btsg-vs-che →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000019584 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Chemed Corp (CHE) reported GAAP revenue of $2.53B (+65.3% vs. FY2024 revenue of $1.53B , and +92.4% cumulative change since FY2023) , GAAP net income of $265.2K, operating cash flow of $388.3M, and free cash flow of $325.5M (-11.5% YoY). On the balance sheet, CHE closed FY2025 with $1.54B in total assets against $251.5M in total debt (Altman Z-Score: 12.68, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.53B	$265.2K	$388.3M	$325.5M	$1.54B	$251.5M
FY2024 (FY)	2024-12-31	$1.53B	$302.0K	$417.5M	$368.0M	$1.67B	$247.3M
FY2023 (FY)	2023-12-31	$1.32B	$272.5K	$330.3M	$271.1M	$3.90B	$911.6M

3. CHE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CHE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CHE compare to HIMS and LFST in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CHE?

Where is CHE trading relative to its 50-day, 200-day, and 52-week technical levels?

CHE last traded at $542.18 (+1.40% on volume of 125,505 shares), positioning the stock +5.36% above its 50-day simple moving average ($514.59) and +16.84% above its 200-day simple moving average ($464.05). Across its 52-week range of $365.21 to $562.24, CHE sits at the 89.8% percentile with a 14-day RSI of 59.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.9% ($515.61 to $568.75).

Direct Sub-Reports: CHE RQD Cockpit CHE 12M Forecast CHE Earnings & Move CHE Dividends & DRIP CHE Insiders & 13F CHE Whale Options CHE Profit Sankey CHE News & Why

ROARABLE RATING BRIEF • RQD 83/100 (A-) ✓ SEC XBRL & RQD VERIFIED

CHE — Chemed Corp: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Chemed Corp (CHE) earns a live Roarable RQD composite score of 83/100, corresponding to a A- letter grade (Roarable Buy) at a spot price of $542.18 (+1.40% 1D, market capitalization $6.96B).

Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 23.4%, gross margin of 32.5%, operating margin of 13.4%, and free cash flow yield of 4.60%.
Whale 13F & Options Flow (16/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (16/20) + Forensic Balance Sheet (18/20): Incorporates a 1.08x equity beta, Altman Z-Score of 12.68, Piotroski F-Score of 7/9, and Debt/Equity of 0.24x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Chemed Corp (CHE) is a NYSE-listed issuer in the Health Care sector, operating in the Medical/Nursing Services industry. — The company carries a market capitalization of $7.1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Chemed Corp (CHE) reported $2.53B in annual revenue (up from $1.53B in FY2024, +65.3% YoY) and $265.2K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.32B revenue, $272.5K net income) through FY2025, CHE scaled operating cash flow to $388.3M and free cash flow to $325.5M, backed by $1.54B in total assets against $251.5M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (A- • RQD 83/100): Strong cash generator (32.5% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $365.21 – $562.24 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh current valuation and 18.5x EV/EBITDA against 13.4% operating margins and a 1.08x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The only sector context provided is that CHE is classified under Health Care and Medical/Nursing Services.

Key Question #1: Can CHE sustain or expand its 13.4% operating margin and 23.4% ROIC against Medical/Nursing Services peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $2.53B and free cash flow of $325.5M, how will capital allocation balance growth reinvestment against $251.5M in total debt?
Key Question #3: How sensitive is CHE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.08x)?

CHE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Chemed Corp (CHE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CHE Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

Chemed (CHE) Tops Q3 Earnings and Revenue Estimates

Yahoo Finance report covering Chemed Corp (CHE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Chemed earnings: what to look for from CHE

The Globe and Mail report covering Chemed Corp (CHE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

LH Stock Hits Record Levels, CHE Stock Surges To Over 52-Week Highs – Here’s What’s Driving Investor Enthusiasm

TradingView report covering Chemed Corp (CHE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Chemed (NYSE:CHE) Stock Breaks Above 200 Day Moving Average - Here's Why

MarketBeat report covering Chemed Corp (CHE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 1d ago

Will Earnings Beat Change Chemed (CHE) Stock Narrative

Simply Wall St report covering Chemed Corp (CHE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Chemed (CHE) Stock Gets Fair Value Bump As Vitas Strength Offsets Roto Concerns

Yahoo Finance report covering Chemed Corp (CHE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Chemed Corporation (NYSE:CHE) Stock Now Rated "Hold" by Sell-Side Analysts

MarketBeat report covering Chemed Corp (CHE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

What Chemed (CHE) Said on Its Q3 Earnings Call

Yahoo Finance report covering Chemed Corp (CHE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CHE Bull vs. Bear Conversation Board — What's Your Call at $542.18?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CHE 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $668.40 (+25.0%)

📌 Pinned Debate

Per the Roarable RQD rating, a 23.4% ROIC and 18/20 forensic balance-sheet score signal a cash-generative, low-leverage business.

Don't sleep on CHE's setup in Health Care. Per the Roarable RQD rating, a 23.4% ROIC and 18/20 forensic balance-sheet score signal a cash-generative, low-leverage business.. Beta of 1.08 means it moves fast when momentum turns, and the 5-pillar RQD gauge (83/100) backs up the fundamental quality.

CapAlloc_Nerd 🐂 BULL

@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Nursing Services. If gross margin (32.5%) holds, EPS grows into the multiple faster than bears think.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $411.73 (-23.0%)

Spot @ $534.72

At EV/EBITDA of 18.5 with the stock near its 52-week high of $562.24, valuation leaves limited margin for error.

Fading this rally in CHE at $534.72. At EV/EBITDA of 18.5 with the stock near its 52-week high of $562.24, valuation leaves limited margin for error.. With a beta of 1.08 and the stock sitting at $534.72 (52-wk range $365.21–$562.24), the easy multiple expansion is already priced in.